アブストラクト
| Title | 心不全治療にFantastic Fourがもたらすものとは |
|---|---|
| Subtitle | 特集 Fantastic Four時代の心不全の治療戦略 総論 |
| Authors | 佐藤宏行 |
| Authors (kana) | |
| Organization | 東北大学病院循環器内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 9 |
| Page | 1713-1718 |
| Year/Month | 2023 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●2020年以降の心不全薬物治療は, Fantastic Fourによるパラダイムシフトが起きている. ●Fantastic Fourとは, ARNI, SGLT2阻害薬, β遮断薬, MRAの心不全治療の4剤併用療法であり, 従来治療よりさらに生命予後が延伸する. ●心不全の診断基準が, 2021年のuniversal definitionによって新たに再定義された. ●心不全ステージ分類を意識した早期からのリスク認識と患者啓発に努める. ●忍容性の高い薬剤から早期(4週間以内)の4剤併用の確立が提唱されている. ●心機能改善後の心不全治療薬の減量・中止は心機能を悪化させるため, 利尿薬減量までに留め, 病状安定後も可能な限り心不全治療薬を継続する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Bozkurt B, et al: Universal Definition and Classification of Heart Failure. J Card Fail, 27:387-413, 2021
- 2) Bauersachs J, et al: Heart failure drug treatment: the fantastic four. Eur Heart J, 42:681-683, 2021
- 3) CONSENSUS Trial Study Group: Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 316:1429-1435, 1987
- 4) M Packer, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 334:1349-1355, 1996
- 5) CIBIS-II Investigator: The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet, 353:9-13, 1999
残りの11件を表示する
- 6) Putt B, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 341:709-717, 1999
- 7) Zannad F, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 364:11-21, 2011
- 8) JJV McMurray, et al: Angiotensin-neprilysin inhibitor versus enalapril in heart failure. N Engl J Med, 371:993-1004, 2014
- 9) JJV McMurray, et al: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 381:1995-2008, 2019
- 10) M Packer, et al: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl Med, 383:1413-1424, 2020
- 11) M Vaduganathan, et al: Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, 396; 121-128, 2020
- 12) JJV McMurray, et al: How should we sequence the treatment for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine. Circulation, 143:875-877, 2021
- 13) L Sien, et al: Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J, 43:2573-2587, 2022
- 14) O Vardeny, et al: Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail, 18:1228-1234, 2016
- 15) BP Halliday, et al: Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): open-label, pilot, randomized trial. Lancet, 393:61-73, 2019
- 16) O Vardeny, et al: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med, 28:2504-2511, 2022
